Cubist Pharmaceuticals Inc

Cubist Pharmaceuticals — Q2 2005 Earnings Presentation

20 slides from Cubist Pharmaceuticals's earnings presentation, Jul 26, 2005

  1. Slide 1: Serious Infections

    Serious | Infections. / howe pened or soppee arts pit regan. facxard he aw vacranetnth erp

  2. Slide 2: Comparison of IV Antibiotic Launches

    Comparison of IV Antibiotic Launches cube Cumulative Gross Sales Since Launch (ICS for CUBICIN®; IMS Non-Retail for others) sez0p. ‘se0p0 ‘stone ‘$80.00 ‘e000 ‘S1T1.7M CUBICIN Sales in First 20 Months a ‘$7000 ‘Cumulative Sales ($000) OO gb OO Cee CEE PCE CCE FP KO ESE HEH EHP FMF EES FS HFK AB-CUBI

  3. Slide 3: Annual Unit Sales: Growing Opportunity

    Annual Unit Sales Growing Opportunity cube 2001 - 2004 Semi-Synthetics: average decline = 5% per year MRSA agents: average growth = 20% per year 35,000 30,000 25,000 20,000 15,000 + 2004 vs. 2003, ‘aed @ [Vancomycin growth +3%| | 5,000 0 2001 2002 2003 2004 MRSA Agents mSemi-synthetics Source: IMS H

  4. Slide 4: Cubist in the News

    Cubist in the News CUBIST Recent Press Following IE News Announcement " Smart Mon Serna MarketWatch } Sosa One-Day Wonder; Hip to Be Square Laveerce Carrel he 20,2008 Biba scars conten. crug news ‘acta Kemedy, CB heath ace appeared in hvesb' Buss Oly) sosron )- Share of Cbit Pramaceie seared eary Ts

  5. Slide 5: Phase 3 Endocarditis/Bacteremia Trial

    Phase 3 Endocarditis/Bacteremia Trial cube + First-ever successfully executed registration study of endocarditis and bacteremia expressly focused on S, aureus + Top line data — Met primary endpoints of non-inferiority in the ITT and PP populations — 235 patients in the ITT population, 139 patients i

  6. Slide 6: CUBICIN International Commercialization

    CUBICIN® International Commercialization Fring Marketing Rights . + Chiron - initial launches expected in 1HO6 — Western and Eastern EU, Australia, New Zealand, India, and certain Central American, South American and Middle Eastern Countries Medison Pharma, Ltd. - launched ~ Israel TTY Biopharm Comp

  7. Slide 7: Significant Infections in U.S. Hospitals

    Significant Infections in U.S. Hospitals CUBIST US Hospital Infections* anon | angeuer™ | Nanccmyee | eee SknvSkn Structure 6644768 | 2,080,805 749,380 25% Bacteremia and Septicemia 3,028,691 733,388 526,244 18% Other Systemic 1015217 269,666 189,524 6% Endocarditis 292,234 67.194 40.412 1% ther Car

  8. Slide 8: 2005 Publications, Posters and Abstracts

    2005 Publ ications, Posters and Abstracts CUBIST ata Fe btn Ske Taye ened Revs RODE aiary Suber Gas hve oddeg cal pa cre) ae ine Teves oe og el ay Oa ape CX NAGASE AGAR RT a ae aby (ISAs as tear po] hay a od wh Sibu Fi ts si) bed pe) ip Vrs iret opal end ee MER aed 7560 aor perce —Asercn ay 2005 re

  9. Slide 9: CUBICIN Commercialization: Manufacturing Capacity

    CUBICIN® Commercialization cuBist Manufacturing Capacity : Ee ee jae zal PO ETTITY oow | 2004 2005

  10. Slide 10: Cubist Current Portfolio

    Cubist CUBIST Current Portfolio ™ | Pre- Reg. Clinical Phase1 Phase2 Phase3 Submiss. Commercial cusien | | Lipo 2| Natural Products. High Througrout Screening]

  11. Slide 11: Daily CUBICIN Net Product Sales

    Dollars in thousands: = Daily CUBICIN® Net Product Sales cuBist Per Shipping Day (Unaudited) 450 400 $401 350 = 300 $339 Ge L| 250 $281 = ‘2 200 I] $207 150 = 100 = 50 H od HW oO Q104 Q204 Q304 Q404 Q105 Q205

  12. Slide 12: Summary Statement of Operations

    Summary Statement of Operations CUBICIN® revenues, net Total revenues Cost of product revenues ‘Other operating expenses ‘Operating loss Other expenses Netloss EPS In thousands except per share data ‘Three months ended ‘June 30, 2005 2008 $25,642 $13,257 28.255 14.795 7am 498 26,960 25,371 iso76) (1

  13. Slide 13: National Trend — New vs. Repeat Accounts

    National Trend — New vs. Repeat Accounts + Increase in number of repeat accounts ordering per day — Roughly 20 additional repeat accounts from March to June + Number of new accounts brought on per day holding steady w= Number of New Account Orders dan05 Feb05 = Mar.05 Avg New Orders Per Day ~®—Avg R

  14. Slide 14: Vials per Account

    8 83 8 Vials per Account Account Ordering Trends ! —_— 40 30 20 10 0 JAN.2005FEB2005 — MAR.2005 APR.2005 —MAY.2005 JUNE. 2005 Nate: Caleutons indude ony those accounts that oder in each gen meth ‘Source: Updated Order Summary Ghrough 6/30/08)

  15. Slide 15: Target Accounts

    Target Accounts CUBIST + Growth within existing and added target accounts since sales force expansion on 4/1 srane00 sana0o srene00 eine — bi st20000 ! - onan f 3 sroso0 z 2 $20,000 = 2 $80,000 2 ql $15,000 5 Esso 2 aq 8 § som sone | a sano “ 0 Jan-05 — Feb-05 = Mar-05 ——Apr-0S original Targets New

  16. Slide 16: Penetration and Formulary Approvals

    Penetration and Formulary Approvals CUBIST by Type of Account Account Type | Potential | Customers | % of Potential ‘% Formulary Customers | Ordering Customers Approval Ordering A 327 308 94% 76% B 540 463 86% 61% Target C 433 325 75% 38% NontargetC | 538, 292 54% Not Tracked DIO 17,830 2.489 14% No

  17. Slide 17: Top Ranked Attributes of CUBICIN

    Top Ranked Attributes of CUBICIN® CUBIST ID Physicians Ranked These Attributes 8* on Scale of 1-10 - o- Effectiveness against MRSA* (Highest rating received!) *+ Convenient dosing ++ Rapidly bactericidal’ *+ Safe in patients with diabetes ++ For patients with inadequate Vancomycin response + Suspect

  18. Slide 18: 2005 CUBICIN Guidance

    2005 CUBICIN® Guidance + CUBICIN revenue range: + Cost of goods sold range: + Operating expense range: — Research and development = Sales and marketing - G&A + Net interest estimate: CUBIST $110 - $120 million 32.8% ~ 30.0% $ 62-64 million $ 43- 45 million $ 19- 20 million $114 - 119 million $7 mill

  19. Slide 19: 2005 Milestones

    2005 Milestones CUBIST + Add supply chain capacity in 1H05 fof ACS Dobtar, second API manufacturing site approved by FDA Ep NDA (CBE. 30) fled fr finnish at Carnal Heath's Botechnotogy and Sterile Life Sciences Facility + Expanded Sales Force ‘Completed 1005 + CORE abstracts/publication submissions

  20. Slide 20: Searchable text section of graphics shown above

    Searchable text section of graphics shown above [L OGO] [GRAPHIC] [LOGO] Statements made during this presentation that are not historical fact may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual r

Cubist Pharmaceuticals — Q2 2005 Earnings Presentation on 6ix